Annexon Q1 2021 Earnings Report
Key Takeaways
Annexon's cash and cash equivalents and short-term investments were $326.7 million as of March 31, 2021. Research and development expenses were $20.7 million for the quarter ended March 31, 2021. Net loss was $26.0 million for the quarter ended March 31, 2021.
Phase 2 trial of ANX005 in Huntington’s Disease (HD) fully enrolled with data anticipated 2H 2021.
First-in-Human dose-ranging trial of ANX009 completed with data expected summer 2021.
Next generation drug candidates, ANX105 and ANX1502, are on track to submit INDs by end of 2021.
Current cash position is sufficient to fund operations through 2023.
Annexon
Annexon
Forward Guidance
Annexon remains on track for another exciting year, and looking ahead, is sharply focused on effectively executing our several clinical programs while advancing multiple next generation drug candidates and driving our beachhead strategy to rapidly expand our platform into mechanistically related indications.